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CHAPTER I 
INTRODUCTION 
Studies utilizing a rat renal cortical slice system (1) or the 
isolated, perfused rat kidney (2), suggest that peripheral dopamine 
directly stimulates renin release through a beta-adrenergic receptor 
mechanism similar to that postulated for norepinephrine by several in-
vestigators (3-8). Recent studies in this laboratory (9-10) utilizing 
the dopamine-beta-hydroxylase inhibitor FLA-63 which effectively pre-
vents the conversion of dopamine to norepinephrine in in vitro tissue 
(11-12), have provided added support for this view as well as for the 
possibility that cyclic AMP may mediate the stimulatory effect of dopa-
mine on renin release via this beta-receptor pathway. However, the re-
sults obtained in these studies have left unanswered the question as to 
whether or not dopamine may also influence renin secretion through an 
interaction with a specific dopamine receptor located in the membranes 
of the juxtaglomerular cells. 
In order to effectively evaluate specific factors that may dir-
ectly control renin release, various humoral and hemodynamic influences 
that also affect renin secretion in vivo must first be eliminated. 
Therefore, an in vitro rat kidney cortical slice preparation devoid 
of these influences was utilized in this study to further examine the 
type of mechanism involved in mediating a direct effect of dopamine on 
renin release. In addition, a number of in vivo and in vitro studies 
1 
2 
have shown that the sensitivity of the renin-secreting cells to catechol-
amine stimulation is potentiated by dietary sodium deficiency (8,9,13,14). 
Thus, cortical tissue obtained from rats maintained on a sodium deficient 
diet was used in this investigation. 
Since further characterization of the receptor type mediating the 
renin responses to dopamine administration is necessary, the present 
study was designed to 1) provide additional in vitro evidence regarding 
the involvement of a beta-adrenergic receptor mechanism in mediating the 
effect of dopamine on renin secretion, by utilizing the phosphodiesterase 
inhibiting agent, theophylline; 2) examine the possibility of dopamine-
specific receptor participation, by evaluating the effect of the dopa-
mine-receptor blocker, d-butaclamol; 3) determine if the renin secretory 
responses to these agents are coupled with tissue cyclic AMP content 
changes at various incubation times; and 4) evaluate if new synthesis 
of renin occurs as a result of administration of these agents to our 
cortical slice preparation. 
CHAPTER II 
LITERATURE REVIEW 
A. Control of Renin Secretion 
There is no question as to the importance of the glycoprotein 
hormone, renin (15), acting as a circulatory proteolytic enzyme, in 
the control of arterial blood pressure (16) and in the primary regula-
tion of aldosterone secretion and thus of sodium and blood volume homeo-
stasis (17-19). The mechanisms participating in the control of renin 
release have been the subject of intensive study for numerous years. 
Three major theories have been proposed to explain how a number of stim-
uli known to affect renin secretion activate the juxtaglomerular cells 
that produce it in the kidney; 1) a "Baroreceptor" or "Stretch Receptor" 
theory states that renin is regulated by changes in tone of the afferent 
arteriolar walls in response to changes in renal perfusion pressure (20), 
2) a "Macula Densa" Theory holds that the rate of renin secretion is in-
versely related to sodium and/or chloride concentration in the distal 
tubular fluid, as sensed by specialized cells in that area (21), and 3) 
a "Neural" Theory postulates that there is a sympathetic nervous regu-
lation of renin secretion either directly through nerve terminals syn-
apsing with the juxtaglomerular cells or indirectly via circulating 
adrenal medullary catecholamines (20). Additional factors such as cir-
culating angiotensin II, antidiuretic hormone (ADH), and intrarenal 
prostaglandins also appear to play a role in the regulation of renin 
3 
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secretion (21) although not as importantly as the three major ones, and 
by mechanisms which are still largely unknown. It is clear, however, 
that in the live animal renin release depends to a large degree upon 
the simultaneous interaction of all of these various stimuli. 
1. Baroreceptor Control of Renin Release 
The development of the baroreceptor concept came about as a re-
sult of studies on renal hypertension. Goldblatt found in the early 
1930's that hypertension of renal origin could be induced by renal ar-
tery constriction and he, therefore, concluded that renal ischemia was 
an important factor stimulating the release of renin from the kidney 
(22). Subsequent studies have demonstrated that reduced renal perfu-
sion pressure rather than an impaired renal blood flow is the primary 
stimulator of renin release (23-25), although they both are interrela-
ted to a certain degree. This view led investigators to study the ef-
fect of changes in perfusion pressure on juxtaglomerular cell granula-
tion as an index of juxtaglomerular cell synthetic activity and metab-
olism. Tobian (26) found an inverse correlation between renal perfusion 
pressure and juxtaglomerular cell granularity, which resulted in his 
support of the existence of an intrarenal stretch receptor in the renal 
afferent arteriole which responds to changes in blood pressure. Added 
evidence for the baroreceptor theory has been obtained through studies 
utilizing the denervated, non-filtering dog kidney model, which effect-
ively isolates the afferent arteriolar mechanism of renin release reg-
ulation for those mediated by the renal nerves and macula densa. Uti-
lizing this model, Blaine and co-workers (27-29) found that the increase 
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in renin release seen after hemorrhage occurred as a result of afferent 
arteriole constriction and decreased renal perfusion pressure despite 
the absence of macula densa and neural influences, supporting the con-
cept of a renal vascular receptor involved in the regulation of renin 
secretion. Furthermore, the renin secretory responses to hemorrhage 
were abolished when this vascular receptor was blocked by administration 
of the smooth muscle relaxant, papaverine, to the denervated, non-filter-
ing dog kidney (30). Some investigators, however, have shown an increas-
ed renin release rate associated with dilatation of the afferent arteri-
ole during renal autoregulation (31,32). 
2. Macula Densa Receptor Regulation of Renin Secretion 
Electron microscopic studies have clearly shown that the macula 
densa cells in the renal distal tubule are in close anatomical associ-
ation with the juxtaglomerular cells (33,34). The macula densa has 
therefore been implicated as an additional regulatory site participating 
in the overall control of renin secretion. Whether the stimulus to the 
macula densa to influence renin release is an increased (35) or decreased 
(24,36,37,38) sodium load to that area, remains unclear. Based on data 
from numerous distal tubule microinjection studies, Thurau and co-workers 
have suggested that it is an increase in sodium concentration rather than 
load, in this area which is the signal influencing renin secretion (39-
41). Meyer et al. (42) and Cooke (43) using osmotic diuretics to in-
crease sodium concentration to the macula densa have confirmed Thurau's 
conclusions. Conversely, Nash (35) has shown that an increase in sodium 
flux across the macula densa cells into the interstitium surrounding the 
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juxtaglomerular cells is responsible for the resulting increase in renin 
' release •. Increased chloride load to the macula densa has also been pro-
posed as the possible signal for renin release (41,44). In contrast, 
Vander's experiments involving the use of diuretics during aortic con-
striction in order to vary distal tubular sodium load without altering 
arterial pressure (38) have led to the view that a decreased sodium 
load to the macula densa results in an increased release of renin. Van-
der (45) and DiBona (46) have conducted experiments in which decreases 
in both distal sodium load and concentration were produced by occluding 
the ureter during mannitol diuresis. Their results further support the 
concept of decreased sodium load to the macula densa as the stimulus 
for renin secretion. 
3. Humoral Control of Renin Release 
Angiotensin II and antidiuretic hormone (ADH) are two circulating 
factors known to exert an inhibitory effect on the secretion of renin 
(47,48). Shade (48), in experiments using dogs with a nonfiltering kid-
ney found that renal artery infusion of angiotensin II or antidiuretic 
hormone inhibits renin secretion. He suggested that these agents exert 
their effects directly on the juxtaglomerular cells. A direct negative 
feedback action exerted by angiotensin II on renin release has been con-
firmed by others in vitro (3) and in vivo (49-51), although the mechan-
ism involved remains unclear. 
Bunag (47) and Vander (52) have confirmed Shade's findings con-
cerning the inhibitory effect of ADH on renin release. Moreover, Ta-
gawa (53) reports that increases in plasma ADH lowers plasma renin ac-
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tivity in sodium deficient dogs. Even though the exact mechanism involved 
in the renin responses to ADH is not known, a direct effect is generally 
accepted. Vandongen's work in vitro supports this view (54). 
Recently, intrarenal prostaglandins have been implicated in Che 
control of renin secretion (61,62). In vitro studies have shown that 
PGE2 increases release of renin whereas PGFll has no effect on renin re-
lease in rabbit renal cortical cell suspensions (55). Gerber (56) has 
also demonstrated in vivo that administration of PGE2 increases plasma 
renin activity. Conversely, Weber et al. (57,58) have shown that PGE2 
has no effect on the secretion of renin in vitro and that PGF2a actually 
decreased release in vitro and depressed plasma renin activity in ~· 
Administration of prostaglandin precursors such as arachidonic acid and 
of prostaglandin synthetase inhibitors such as indomethacin are known to 
increase and decrease plasma renin activity, respectively, in the rabbit 
(59). Using filtering and nonfiltering kidneys in anesthetized dogs, 
Seymour and Zehr (60) have shown that various intrarenal prostaglandins 
have a direct effect on the juxtaglomerular cells to increase renin re-
lease. In view of these conflicting data, further investigation is in 
order to evaluate a possible regulatory action of prostaglandins on the 
release of renin. 
4. Neural Control of Renin Release; Action of Sympathetic Nerves and 
Catecholamines 
The kidney cortex is innervated by the lesser splanchnic nerve, 
a branch of the sympathetic nervous system (63), and a great supply of 
sympathetic nerve terminals in close association with the juxtaglomeru-
8 
lar cells has been demonstrated (64-67). Thus, approximately two dec-
ades ago~ a direct neurogenic control of renin secretion was postulated 
and a large body of evidence supporting this concept has been provided 
since then (68-72). A significant decrease in renin release occurs when 
the kidney is denervated (69,70). Electrical stimulation of the renal 
nerves in the nonfiltering kidney results in an increase in the release 
of renin when the baroreceptors are inactivated (71). In some experi-
ments, renal vasoconstriction has been observed in association with an 
increased renin activity after renal nerve stimulation (72). 
Besides the peripheral neural control of renin release, central 
nervous system stimulation has also been shown to modify renin responses 
via the renal nerves (73-75). In these studies, electrical stimulation 
of the midbrain (73), pons (75), or medulla (74) increased renin release. 
In all cases, the responses were abolished by renal denervation. How-
ever, Ueda (73) observed a simultaneous increase in circulating catechol-
amines associated with diminution of the renin responses to midbrain 
stimulation after renal denervation. He thus suggested that the central 
nervous system regulates release of renin through a circulating catechol-
amine mechanism. Furthermore, the catecholamines epinephrine and nore-
pinephrine (71,76) and tyramine (77), an amine capable of releasing nor-
epinephrine from nerve endings (78), are known to stimulate renin release 
when infused directly into the renal artery. In a recent study by John-
son (79), epinephrine and isoproterenol infused into the inferior vena 
cava caused a marked increase in plasma renin activity, whereas renal 
artery infusion of epinephrine did not increase plasma renin activity. 
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L-propranolol blocked the increase in plasma renin activity caused by 
vena cava infusion of epinephrine, suggesting an extrarenal beta-recep-
tor mediation. 
On the other hand, norepinephrine administration induces release 
of renin when infused intravenously during aortic constriction (72) al-
though Wathen et al. (76) disputes this. Intravenous infusion of nor-
epinephrine and isoproterenol increases renin secretion acco~ding to 
Ueda (80), a response that is inhibited by administration of propranolol 
and not affected by denervation. Thus, sympathetic catecholamines may 
act either directly on the juxtaglomerular cells to stimulate renin re-
lease or indirectly by affecting the intrarenal receptors. 
The direct effect of catecholamines on renin secretion has been 
studied extensively utilizing various agonistic and antagonistic agents 
in vitro to determine the mechanism mediating the renin release responses 
to these agents (3-10, 14, 81-86). Renal cortical slices (5-10,14), ren-
al cortical suspensions (81), isolated glomeruli (84), or isolated per-
fused kidney preparations (85,86) have been used in these studies to 
evaluate a number of factors which may directly influence renin release, 
and Braverman (87), Hammersen (88), and Corsini (89) have shown that ren-
in release in vitro is a metabolically active process. 
It is generally agreed from these in vitro studies that a beta-
adrenergic receptor mechanism is involved in the mediation of the stim-
ulatory effect of norepinephrine on renin secretion (3-6,8,81-83) and 
that this mechanism appears to utilize cyclic AMP as the intracellular 
messenger (4-6,8-10,14-81). Support for cyclic AMP participation has 
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been obtained in in vivo (91-94) and in vitro (3,4,95,96) studies utiliz-
ing the phosphodiesterase inhibitor theophylline which effectively pre-
vents the intracellularly generated nucleotide from being degraded, thus 
potentiating the renin secretory responses to catecholamine stimulation. 
The type of beta-adrenergic receptor that is involved in the dir-
ect regulation of renin release is still under debate. Some studies 
have shown that renin release responses are mediated via a beta1 or car-
diac type receptor (97-99) while others (83,100) have demonstrated that 
a betaz-type (peripheral vascular type) is inv9lved. 
In addition to the stimulatory effect On renin release exerted 
by norepinephrine via a beta-adrenergic receptor mechanism, Lopez et al. 
(9) have shown that stimulation of renal alpha-adrenergic receptors by 
large concentrations of norepinephrine inhibits renin secret2~n and that 
this effect is coupled with decreases in tissue cyclic AMP. This concept 
of alpha-adrenergic receptor inhibition of renin release was clearly dem-
onstrated by the fact that addition of alpha-adrenergic receptor antagon-
ist agents result in removal of the renin release inhibition caused by 
norepinephrine. This view has been supported by others working with the 
isolated rat kidney (101), the cortical slice system (4,7,8), or the live 
animal (102). 
5. Dopaminergic Regulation of Renin Release 
Dopamine is a catecholamine (3,4-dihydoxybenzene) (103) which is 
structurally similar to its beta-hydroxylated derivative, norepinephrine. 
Studies of the actions of dopamine indicate that many metabolic effects 
produced by this catecholamine are different from those caused by nor-
ll 
epinephrine (104-112), suggesting the existence of dopamine-specific re-
ceptors. For instance dopamine turnover rates are greater in certain 
areas of the brain than others even though norepinephrine concentration 
is the same (113). Also, despite the fact that over 50% of the total 
catecholamine content of the mammalian brain is dopamine, Carlsson (114-
115), Sano (116), and others (117-118) have demonstrated that brain dopa-
mine, unlike norepinephrine, is concentrated in a few specific areas, 
namely the corpus striatum of the basal ganglia and substantia nigra of 
the mesencephalon. Additionally, dopaminergic neurons are identifiable 
in the hypothalamus (119-120) , possibly terminating at the origin of the 
hypophyseal portal system (119). These neurons are thought to play a 
role in the regulation of prolactin (121-122) and gonadotropin (123) re-
lease from the anterior pituitary gland. 
In addition to its role as a neurotransmitter in the midbrain 
and hypothalamus, numerous studies have shown that dopamine can exert 
peripheral effects on organs controlled by the autonomic nervous system 
(124) and on the coronary (104-106) and renal (108-112) vasculature. 
Specifically, dopamine is known to 1) increase cardiac muscle force of 
contraction and heart rate by an action on beta-adrenergic receptors 
(104-106), 2) exert an effect on alpha-adrenergic receptors to cause 
vasoconstriction in peripheral vascular beds (104,107) and 3) produce 
vasodilatation in the kidney (108-110) via specific dopaminergic vas-
culature receptors (110-112). McDonald and Goldberg (125) have shown 
that intravenous infusion of dopamine stimulates renal blood flow, and 
increases glomerular filtration rate and sodium diuresis. Most of these 
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renal effects by dopamine are inhibited by haloperidol, a specific dopa-
mine-receptor blocking agent (112,126). These findings are supportive 
of the existence of a specific vascular receptor by which dopamine causes 
renal vasodilatation and have recently been confirmed by Nakajima (127). 
Dopamine has been identified in the kidney of several species 
(128-129), and the release of dopamine from sympathetic nerves (130) and 
the adrenal medulla (131) has been demonstrated. Because of these obser-
vations, and in view of the evidence Goldberg has produced in support of 
the existence of a specific dopamine receptor in the renal vasculature, 
a number of laboratories are currently evaluating the potential role 
which dopamine may play in the regulation of renin release from the renal 
juxtaglomerular cells. 
Various in vivo studies have demonstrated that dopamine either 
increases (132-134) or decreases (135-136) renin secretion in the dog 
or in man. Such conflicting evidence is not unusual in view of the num-
ber of factors in the live animal which simultaneously interact to in-
fluence renin release. Thus, in vitro studies have been undertaken in 
which the direct effects of dopamine may be more effectively studied, 
in the absence of hemodynamic, humoral, and other in vivo influences 
(1,2,9,10). 
Utilizing a rat renal cortical slice preparation, Henry et al. 
(1) found that addition of dopamine at concentrations of 10-5M or greater 
significantly increased renin release, and that the known beta-adrenergic 
receptor blocker, propranolol, prevented the stimulatory effect of dop-
amine on renin secretion. They concluded that dopamine directly stim-
13 
ulated renin release by a mechanism involving a beta-adrenergic receptor, 
a view supported by recent observations of Quesada (2). Additionally, 
Lopez et al. (9,10) have shown that this direct stimulatory effect of 
dopamine on renin release is coupled with tissue cyclic AMP changes, 
which suggest the involvement of adenyl cyclase in the stimulatory path-
way. 
Data from studies by Nakajima et al. (127,137) utilizing spiro-
peridol, a dopamine receptor antagonist, in a rat kidney particulate 
preparation indicate that specific dopamine receptors mediate the ele-
vation of cyclic AMP levels in renal tissue after addition of dopamine 
leading to renal vasodilation. These observations by Nakajima and those 
seen in our laboratory (9,10) constitute evidence for the existence of 
a cyclic-AMP-mediated receptor mechanism by which dopamine influences 
renal mechanisms. However, these data do not elucidate whether or not 
dopamine may influence renin secretion through an interaction with a 
specific dopamine receptor, as opposed to its clear beta-adrenergic re-
ceptor mediation on renin release. Furthermore, recent evidence by 
Kebabian suggests that more than one type of dopamine receptor exists 
(138). In view of these conflicting results, further characterization 
of the receptor type mediating the renin responses to dopamine is in 
order. 
c:IAPTER II I 
MATERIALS AND METHODS 
Thirty-six male Sprague-Dawley rats (Sprague-Dawley Co., Madison, 
Wisconsin) with initial weights of 210 + 10 g were used in this study. 
They were kept in a temperature-and-light-controlled room (23 ± 2°C; 12 
hour light-12 hour dark photoperiod), two animals per cage, with unlim-
ited access to distilled, deionized water. The animals were fed a sodi-
um-deficient diet (Teklad Test Diet Co., Madison, Wisconsin), providing 
less than 0.02 mEq of sodium per day for a period of 10-20 days. They 
were subsequently sacrificed by decapitation and their kidneys excised 
and placed in Robinson's buffer at 4°C (139). The isolated kidneys 
were then gassed again for'30 sec with the same gas mixture. 
Slices of renal cortex, approximately 0.3 mm thick, were prepared 
from the decapsulated kidneys using a Stadie-Riggs microtome (A. Thomas 
Co.). Each slice was subsequently divided into six similarly-sized sec-
ti~s which were randomly distributed to incubation beakers containing 
2.5 ml of Robinson's buffer media at 4°C. The procedure was repeated 
using slices from other cortical areas until each beaker contained 50 + 
30 mg of homogeneously distributed cortical tissue. The sliced tissue 
was preincubated at 37°C for 15 min in a Shaking Dubnoff Metabolic In-
cubator (Precision Scientific Co.) under an atmosphere of 95% 02 - 5% 
co2 • The preincubated tissue was then transferred to beakers containing 
2.5 ml of fresh Robinson's buffer at 37°C and incubated for 5,20 or 60 
14 
15 
minutes under identical conditions as in the preincubation period. 
One of each group of six tissue-containing beakers was used as 
an untreated:. control sample, while the remaining tissue samples were 
treated with dopamine (1o-3M; Sigma):. added either alone or in conjunc-
tion with the dopamine-receptor blocking agent d-butaclamol (1o-6M; Ayer-
st), its inactive isomeric form 1-butaclamol (10-6M), or the phosphodi-
esterase inhibitor theophylline (1o-3M). D- and 1-butaclamol and theo-
phylline were also administered alone to the tissue preparation. In a 
simultaneous study:. the specific dopamine receptor agonist, apomorphine 
(10-~), was added to the tissue preparation either alone or with dop-
amine (10-3M). The dopamine beta-hydroxylase inhibitor FLA-63 (10-4M; 
Regis) was added to all samples to prevent conversion of dopamine to 
norepinephrine in the tissue system (11,12). 
Theophylline:. the blocking agents, apomorphine, and FLA-63 were 
added to the tissue preparation prior to both the pre-incubation and 
incubation periods, while dopamine was added prior to the incubation 
period only. D- and 1-butaclamol, dopamine, apomorphine, and FLA-63 
were preparaed in a 0.1% ascorbic acid solution (Sigma) to prevent oxi-
dation (5), while theophylline was prepared in Robinson's buffer. 
Following incubation:. the supernatant medium was collected and 
stored at -20°C until assayed for renin concentration by angiotensin I 
radio~unoassay (142). The incubated tissue was immediately frozen 
on dry-ice, homogenized in 1 ml of 8% trichloracetic acid:. transferred 
to tubes containing 5 drops of 0.1 N HCl, vortexed for 5 sec, and stored 
at -20°C until assayed for cyclic AMP content by a modification of the 
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protein-binding assay of Gilman (141). In some instances, the incubated 
tissue was collected for determination of its renin content. The tissue 
was purified by a series of dialysis steps and measured for renin concen-
tration by radioimmunoassay of angiotensin I. 
A. Determination of Renin Concentration 
Renin concentration in incubated supernatant was estimated in-
directly by measuring the amount of angiotensin I generated when aliquots 
of the renin-containing samples were allowed to react with dog renin sub-
strate in the presence of an appropriate inhibitor of converting enzyme 
and angiotensinases. When these enzymes are inactivated, the accumula-
tion of angiotensin I during a given generation period reflects renin 
activity. Blockade of converting enzyme and angiotensinase activity was 
achieved in this study by the use of a 1% solution of phenylmethylsul-
fonylfluoride (PMSF; 142). 
To generate angiotensin I, the frozen samples were thawed in an 
ice bath at 4°C and vortexed for ten seconds. Aliquots of 0.025 m1 
frGm each sample were then transferred to tubes containing 0.1 m1 of 
saturated NaCl. Six-hour nephrectomized dog plasma containing renin 
substrate (angiotensinogen) and previously treated with PMSF (0.05 ml/ml 
plasma) was then added to each tube (0.4 ml/tube). The mixture was in-
cubated for one hour at 37°C and diluted with one m1 of distilled, de-
ionized water. The samples were vortexed for five sec, covered with 
aluminum foil, and placed in a boiling water bath for three min to pre-
vent further angiotensin I generation. The samples were then allowed 
to cool to 25°C and stored at -20°C. The amount of angiotensin I gener-
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ated was measured by a modification of Angiotensin I ( 125I) Radioimmuno-
assay (N~w England Nuclear) • Renin concentration was expressed in ng/mg/ 
hr -(ng of angiotensin I generated/ mg of tissue/ hour of generation) • 
B. Tissue Renin Determination 
Tissue collected for determination of renin content was homogen-
ized in 1 m1 of 0.9% NaCl at 4°C and centrifuged for 15 min at 3500 g. 
The supernatant was subsequently dialyzed for 24 hours against an EDTA-
acetic acid buffer (pH 3.3), followed by heating to 32oc for 1 hour to 
selectively denature endogenous renin substrate and angiotensinases, 
and dialyzed again for 24 hours against an EDTA-phosphate buffer (pH 
7.5) as described by Skinner (143). 
The purified tissue homogenates were then used to generate angio-
tensin I as described previously and subsequently measured for renin con-
centration by Angiotensin I (125I) Radioimmunoassay (New England Nucle-
ar) • The values were expressed in ng of angiotensin I generated/ mg wet 
tissue/ hour of generation. 
C. Determination of Tissue Cyclic Adenosine 3',5'-Monophosphate (cAMP) 
Content 
The frozen tissue homogenates collected for cAMP determination 
were thawed in an ice bath at 4°C, and centrifuged at 4000 g for ten 
min at 4°C. The supernatant was transferred, while the protein pellet 
was discarded. Two m1 of water-saturated ether were added to each 
sample, vortexed for ten sec, and the ether phase aspirated and dis-
carded. This extraction procedure was repeated three additional times. 
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The cAMP-containing water soluble phase was then decanted into vials 
previously placed on dry ice~ and the frozen samples were subsequently 
lyophyilized. The lyophilized material was then stored at -2ooc until 
assayed for cAMP content by a modification of the competitive protein 
binding assay of Gilman (141) • Tissue cAMP concentration was expressed 
in pmol/mg (pmol of cAMP/mg wet tissue). 
Calculations 
Statistical significance of the data was evaluated by Student's 
paired and unpaired t tests using a programmable desk top calculator 
(Hewlett-Packard) at Argonne National Laboratory (Argonne~ Illinois). 
A Linear Regression Analysis was performed on the control data (144) • 
CHAPTER IV 
RESULTS 
Resting renin release and tissue cyclic AMP content of untreated 
(control) renal cortical tissue from sodium deficient rats are shown in 
Fig. 1. Renin release increased linearly with time of incubation (r: 
0.62; p < 0.001). In contrast to renin, tissue cyclic AMP content val-
ues were maximal at 20 min of incubation and decreased by 60 min to lev-
els seen at 5-m.in incubation. 
The effect of 1o-3M dopamine on three parameters, renin release, 
tissue renin content, and tissue cyclic AMP at various incubation times, 
is depicted in Fig. 2. Renin release responses to dopamine administra-
tion gradually increased over control by 5 and 20 min and were signifi-
cantly greater by 60 min. In contrast, cyclic AMP content values in re-
sponse to added dopamine appeared significantly greater than those of 
control samples as early as 5 min of incubation. Although mean tissue 
renin content of the dopamine-treated samples appeared higher than that 
of controls by about 60 nanograms at 60 min, this difference was not 
statistically significant. 
The effect of the phosphodiesterase inhibitor theophylline 
(10-3M) added alone or together with dopamine (1o-3M) on the same three 
parameters in relation to time of incubation, is demonstrated in Fig. 3. 
Theophylline appeared to increase the renin release responses to added 
dopamine at 20 and 60 min, while significantly potentiating the cyclic 
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AMP responses to dopamine administration at the same time periods. Theo-
phylline py itself significantly increased renin release by 60 min, not 
only in relation to controls but in regard to dopamine alone (p < 0.02). 
Cyclic AMP content changes in response to theophylline alone were signifi-
cantly potentiated when compared to those exerted by dopamine alone at all 
times of incubation (p < 0.01, p < 0.02, p < 0.02 for 5,20, and 60 min, 
respectively), but were not different from those seen in response to 
theophylline plus dopamine treatment at corresponding.times. 
Mean tissue renin content at 60 min appeared increased by about 
25 nanograms in response to theophylline plus dopamine and by an additi-
onal 85 nanograms in the presence of theophylline alone when compared 
to that observed in response to dopamine added alone, although these dif-
ferences were not significant. 
Addition of the specific dopamine-receptor blocker d-butaclamol 
(1o-6M) to the cortical slice preparation increased the mean renin re-
lease levels in relation to those seen with dopamine alone at 60 min, 
but not significantly (Fig. 4). Also, d-butaclamol administration did 
not further alter the significant stimulation of tissue cyclic AMP lev-
els seen with dopamine alone at the same time period. By itself, d-buta-
clamol had no effect on renin release or tissue cyclic AMP content. Mean 
tissue renin content in the presence of d-butaclamol added together with 
dopamine was increased by about 40 nanograms in relation to that seen in 
response to dopamine alone, but the difference was not significant. 
L-butaclamol at 1o-6M, added alone or with dopamine was inef-
fective in altering the renin release and cyclic AMP levels seen with 
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dopamine alone (Fig. 5). A 60 nanogram increase in tissue renin content 
occurred .in response to dopamine plus 1-butaclamol treatment relative to 
control at 60 min, but this difference was again not significant. 
Figure 6 summarizes the results of this study utilizing theophyl-
line and d-butaclamol, and those obtained in a parallel study with apomor-
phine, a dopamine-receptor agonist. From this figure it is clear that in 
addition to the data reported in this section, apomorphine (1o-6M) preven-
ted the stimulatory effect of 1o-3M dopamine on renin release and cyclic 
AMP content at 60 min incubation. The overall significance of these ob-
servations will be discussed. 
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Figure 1. Renin release rate and tissue cyclic AMP content of unstim-
ulated (control) renal cortical slices from sodium deficient rats 
at incubation times of 5, 20, and 60 min. The renin release data 
represent the mean control value + S.E. of 14-32 observations for 
each time period. Similarly, the cyclic AMP content data represent 
the mean control value + S.E. of 12-14 observations for each time 
period. The dopamine beta-hydroxylase inhibitor FLA-63 (10-4M) was 
added to all samples in this and subsequent experiments. 
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Figure 2. Effect of 1o-3M dopamine on renin release, tissue cyclic 
AMP content, and tissue renin content of renal cortical slices from 
sodium deficient rats. The data represent the mean renin release 
rate+ S.E. of 14-32 observations, and the mean tissue cyclic AMP 
content+ S.E. of 12-14 nontreated (control) and dopamine-treated 
samples at various incubation times. The data also show that mean 
tissue renin content+ S.E. of 23 observations in control and dop-
amine-treated samples at 60 min incubation. 
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Figure 3. Changes in renin release, tissue cyclic AMP content, and 
tissue renin content, in response to 1o-3M dopamine and 1o-3M theo-
phylline, added together or separately to renal cortical slices 
from sodium deficient rats. The data represent the mean renin re-
lease change + S.E. of 7-13 observations, the mean tissue cyclic 
AMP content change± S.E. of 9-11 observations for each treatment 
at 3 incubation times. The mean renin release rates for nontreated 
(control) tissue at 5, 20, and 60 min incubation were 2.55 + .276 
ng/mg wet tissue/hr, 3.86 + .801 ng/mg/hr, and 10.28 + 1.01 respec-
tively. The corresponding mean control cyclic AMP content values 
were, respectively, .397 + .032 pmol/mg, .616 + .076 pmol/mg, and 
.437 + .046 pmol/mg. The mean control tissue renin content at 60 
min was 1419 + 103 ng/mg/hr. 
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Figure 4. Changes in renin release, cyclic AMP content, and tissue 
renin content in response to 10-3M dopamine and 10-6 d-butaclamol, 
added together or separately to renal cortical slices from sodium 
deficient rats. The data represent the mean renin release change 
+ S.E. of 2-18 observations, the mean tissue cyclic AMP content 
change + S.E. of 2-12 observations, and the mean tissue renin con-
tent change+ S.E. of 13 observations for each treatment at various 
incubation times. The mean control (nontreated) values for renin 
release rate, tissue cyclic AMP content, and tissue renin content, 
for each time period are the same as those in Figure 3. 
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Figure 5. Changes in renin release~ tissue cyclic AMP content, and 
tissue renin content in response to 1o-3M dopamine and 1o-6M 1-
butaclamol, added alone or together to renal cortical slices from 
sodium deficient rats. The data represent the mean renin release 
change+ S.E. of 4-14 observations, the mean tissue cyclic AMP con-
tent change+ S.E. of 2-11 observations, and the mean tissue renin 
content change + S.E. of 10 observations for each treatment at vari-
ous incubation times. The mean control (untreated) values for ren-
in release rate, tissue cyclic AMP content, and tissue renin content, 
for each time-period are the same as those described in Figure 3. 
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Figure 6. Changes in renin release, tissue cyclic AMP content, and 
tissue renin content in response to dopamine (1o-3M) added alone 
or together with 1o-3M theophylline, 1o-6M d-butaclamol, or 1o-6M 
apomorphine, to renal cortical slices from sodium deficient rats. 
The data represent the mean renin release change± S.E. of 2-18 
observations, the mean tissue cyclic AMP content change± S.E. of 
2-12 observations, and the mean tissue renin content change+ S.E. 
of 9-24 observations for each treatment at various incubation times. 
The mean control (untreated) renin release rate, tissue cyclic AMP 
content, and tissue renin content at various times of incubation, 
are the same as those indicated in Figure 3. The corresponding 
' 
mean control values at 3 incubation times, for treatments involving 
dopamine alone or together with apomorphine were, respectively, 
2.56 + 0.48, 4.69 + 1.51, and 10.60 + 1.39 ng/mg/hr for renin re-
lease; 0.39 + 0.03, 0.53 + 0.09, and 0.45 + 0.01 pmol/mg for cyclic 
AMP content; and 489 + 399 ng/mg/hr for tissue renin content at 60 
min. 
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CHAPTER V 
DISCUSSION 
Renal cortical slice preparations have been successfully utilized 
in numerous studies to evaluate the direct effect of catecholamines and 
other agents on renin release (5-10, 14), or to examine renin secretory 
rates in unstimulated cortical tissue (6, 90, 145, 146). The results 
obtained in this study support previous observations in studies utilizing 
rat kidney slice systems (6, 90, 145, 146), that renin release in resting 
renal tissue is directly proportional to time of incubation which is to 
be expected of metabolically active, oxygen-consuming (147) endocrine 
tissue. Furthermore, these data provide added evidence for the postu-
lation that resting renin secretory rates in renal -slices from sodium 
deficient rats are comparably greater than those seen in sliced tissue 
obtained from rats maintained on sodium replete diets (6, 90, 145), 
which may reflect an increased responsiveness of the juxtaglomerular 
cells in the sodium deficient state. 
Studies in this laboratory (9,10) have recently shown that dop-
amine at 1o-3M can directly stimulate renin release through a beta-ad-
renergic receptor mechanism apparently mediated by tissue cyclic AMP 
changes, which confirm previous observations by Henry ( 1) and Quesada 
(2). The data generated in the present study offer further support for 
the concept of a cyclic AMP-mediated beta-receptor regulation of renin 
release by dopamine, by demonstrating that cyclic AMP content of the 
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incubated tissue in response to dopamine administration was significantly 
increased over that of controls as early as 5 min of incubation, whereas 
renin release appeared significantly stimulated only after 60 min of in-
cubation. These observations are consistent with the model proposed by 
Sutherland (148) regarding mediation of stimulus-hormonal responses by 
adenylate cyclase/cyclic AMP, and they agree with the postulated beta-
adrenergic receptor mechanism of action by which other catecholamines 
stimulate renin secretion (3,5,7-10). Furthermore, the results of this 
study utilizing the phosphodiesterase inhibitor theophylline, provide 
added evidence for this concept by showing that both tissue cyclic AMP 
and renin secretory rates were potentiated in the presence of this agent, 
as suggested in previous studies with other catecholamines (4,81). Al-
though the data are not conclusive in this regard, the apparent increase 
in tissue renin content in response to dopamine and theophylline admini-
stration in this study, may be suggestive of new synthesis of renin in 
addition to increased release as suggested by Katz in studies with dog 
renal cortical slices (149). Effective binding of dopamine to receptors 
other than dopamine-specific ones is not unusual, since Goldberg (150) 
has demonstrated that this amine has the biochemical flexibility to bind to 
beta- and perhaps also to alpha-adrenergic receptors. Thus, it appears 
that dopamine stimulates renin release by a beta-adrenergic receptor 
mechanism, a view supported by other investigators (1,2,10) who have 
shown that the stimulatory effect exerted by dopamine on renin release 
can be suppressed by addition of the beta-receptor blocker, propranolol. 
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Recently, Quesada et al. (2) have produced evidence showing that 
the dopamine-receptor blocking agent, haloperidol, potentiates the renin 
release responses to dopamine administration. The results of the present 
study utilizing the dopamine-receptor blocker, d-butaclamol, agree with 
their observations and further suggest that dopamine-specific receptors 
may have no effect or may participate in an inhibitory fashion in the 
regulation of renin release. Whether or not tissue cyclic AMP is also 
involved in mediating this apparent inhibitory control of renin secre-
tion by dopamine is not clear, since d-butaclamol administration did 
not further alter the content of the nucleotide in relation to that 
seen with dopamine alone. However, data from another study using the 
dopamine-receptor agonist agent, apomorphine, appear to indicate that 
decreases in tissue cyclic AMP content may mediate the action of the 
inhibitory component of dopamine, in view of the fact that specific 
stimulation o·f dopamine receptors by this agent prevented the increase 
in renin release and tissue cyclic AMP content observed with dopamine 
alone. Thus, dopamine may stimulate renin release via a beta-receptor 
mechanism involving cyclic AMP content changes and it may inhibit it by 
its interaction with a dopamine-specific receptor. 
Although the possibility of a dual regulatory control exerted 
by dopamine on renin secretion is attractive and a similar concept has 
been postulated in regard to the regulation of renin release by norepine-
phrine (6,8,101,102), further work is needed to determine if the apparent 
inhibition mediated by a dopamine receptor is real, since the results seen 
in this study with the inactive isomer, 1-butaclamol (151) are contradic-
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tory and do not fit the proposed model. Therefore, additional doses of 
apomorphine and d,- and 1-butaclamol need to be evaluated and other known 
dopamine-receptor agonist and antagonist agents must be examined, before 
this question can be effectively answered. 
In summary, the data reported in this study suggest that, 1) 
dopamine is capable of directly stimulating the renal juxtaglomerular 
cells to influence renin release via a beta-adrenerg~c receptor mechan-
ism involving tissue cyclic AMP changes; 2) new synthesis of renin, in 
addition to stimulation of its release, may result from the interaction 
of dopamine with this postulated beta-adrenergic receptor; and 3) dop-
amine may also exert a simultaneous inhibitory regulation of renin re-
lease via a dopaminergic-receptor mechanism, but further investigation 
is needed before this possibility can be properly evaluated. 
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